The first study on this came just a week ago from the US. The American Centers for Disease Control and Prevention are looking into reports that a very small number of teenagers and young adults, vaccinated against the coronavirus, he may have had heart problems. Now also from Israel, one of the countries that has shown greater speed in the vaccination campaign carried out exclusively with the Pfizer-Biontech vaccine. comes a search in this sense. The Israeli health ministry has announced that it has found a number of myocarditis – inflammation of the heart muscle – in young men who have received the vaccine and these are probably related to immunization.
Pfizer – consulted and quoted by the newspaper Haaretz – stressed that he had not observed a higher rate of the disease than is normally found in the general population. Cases in Israel – the ministry said – there were 275 between December last year and May 2021 out of over 5 million vaccinated. Most of the patients – according to the study carried out by the ministry – were not more than 4 days in hospital and 95% of these cases were defined as mild. The ministry study therefore found that “c‘is a probable link between those who received the second dose of Pfizer and myocarditis in young men between 16 and 30 years old“. Pfizer – quoted by the newspaper – replied that it was aware of the Israeli study, adding that a causal link between the vaccine and inflammation has not been established.
On May 28, the European Medicines Agency (EMA) authorized the vaccine for the 12-15 age group and the hypothesis of myocarditis was taken into consideration. The safety committee of the EMA is evaluating very rare cases of myocarditis (inflammation of the heart muscle) e pericarditis (inflammation of the membrane around the heart) that occurred after vaccination with Comirnaty (Pfizer-Bionteche), mainly in people under the age of 30. “Currently – explains the agency in a statement – there is no indication that these cases are due to the vaccine and the EMA is closely monitoring this problem”. Despite this uncertainty, the committee found that the benefits of Comirnaty in children aged 12 to 15 years outweigh the risks, particularly in children with conditions that increase the risk of serious Covid. The safety and efficacy of the vaccine in both children and adults will continue to be closely monitored as it is used in vaccination campaigns in Member States, through the EU pharmacovigilance system and ongoing and additional studies by the company. and the European authorities.
Support ilfattoquotidiano.it: your contribution is essential
Your support helps us ensure our independence and allows us to continue producing quality online journalism that is open to all, without paywalls. Your contribution is essential for our future.
Become a supporter too